India's leading pharmaceutical-grade nicotine pouch manufacturer for the US export market. CDSCO (Indian FDA) licensed facility, WHO-GMP certified, with over 3 million pouches per month production capacity since 2018.
India is one of the world's top pharmaceutical exporters. Our nicotine pouch manufacturing operates to the same pharma standards that have made India a trusted global supplier to the US, EU, and beyond.
The Central Drugs Standard Control Organisation is India's equivalent to the US FDA. Our pharmaceutical manufacturing license is granted and overseen by CDSCO — the highest regulatory standard for drug manufacturing in India.
World Health Organization Good Manufacturing Practice certification. The same international standard demanded by the EU, US, and 100+ regulated markets. Traceable batches, documented processes, and validated equipment throughout.
Our on-site laboratory performs full analytical testing on every production batch — nicotine concentration (HPLC method), microbiological purity, ingredient identity verification, and stability testing.
Manufacturing nicotine products for export from India is fully legal. India's COTPA domestic-sale regulations do not apply to export production. We operate under CDSCO pharma licensing — the correct legal framework for export manufacturing.
India's Cigarettes and Other Tobacco Products Act (COTPA 2003) regulates the domestic sale and distribution of tobacco products within India. Critically, COTPA's restrictions on nicotine product sales do not extend to manufacturing for export — this position is consistent with how India regulates pharmaceutical exports more broadly.
Nicotine pouches manufactured for export are classified under CDSCO pharmaceutical licensing, not FSSAI food regulations (which ban tobacco/nicotine in food products domestically). Our facility operates under this CDSCO pharmaceutical framework — the same regulatory pathway used by India's $27 billion pharmaceutical export industry.
India exported approximately 456 metric tons of nicotine-related products in 2024 (~$40M+), cementing its position as a globally trusted nicotine supply chain source for markets including the United States, European Union, and United Kingdom.
Every production run follows our validated pharmaceutical manufacturing protocol — no shortcuts, no exceptions, regardless of order size.
Every incoming ingredient — pharmaceutical nicotine, base materials, flavoring agents — is tested against CoA specifications before entering production.
USP-grade pharmaceutical nicotine mixed under controlled conditions. Concentration verified by HPLC before advancing to formulation.
Automated filling to precise weight specifications. Each pouch sealed under validated process parameters. In-process weight checks at defined intervals.
Filled pouches loaded into cans, sealed, and packaged per your label specifications — 15 or 20 ct per can, with compliant FDA warning labeling.
Finished product samples from every batch submitted to our in-house lab. Certificate of Analysis issued after passing all quality release specifications.
Batch records, CoA, ingredient declarations, and Indian customs export paperwork prepared. Your full compliance document package is assembled and delivered with each shipment.
We welcome virtual facility tours for serious buyers. Contact us to schedule a walkthrough and discuss your production requirements.